09.02.26 -- Engineering Tregs To Target Solid Tumors With CoRegen's Dr. Sonal Gupta

CAR-T therapies drive 73% of active pipeline programs, yet solid tumors remain out of reach. Explore what the next wave of progress means for your strategy.

See how continuous in-line monitoring of glucose and lactate levels provides highly accurate, real-time data on cellular metabolism without the risks or data gaps associated with manual periodic sampling.

Discover how high-throughput electroporation screening compresses CAR-T optimization timelines while delivering reproducible, scale-ready results across donors.

Learn how to determine the linear range for western blot quantification using total protein stains or housekeeping proteins to ensure accurate normalization and avoid saturation effects.

Neurodegenerative disease research faces a critical gap between symptom management and disease modification, making better preclinical models an urgent priority for the field.

Early stable CHO expression data reveal manufacturability issues in complex antibodies that transient screening misses, with case studies showing how this changes lead selection.